Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.72
- Piotroski Score 5.00
- Grade Overweight
- Symbol (RDY)
- Company Dr. Reddy's Laboratories Limited
- Price $15.09
- Changes Percentage (-0.72%)
- Change -$0.11
- Day Low $15.00
- Day High $15.28
- Year High $16.89
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
- Last Earnings 05/09/2024
- Ex-Dividend for 5/16 Dividend 07/30/2024
- Dividend Payable 08/12/2024
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $4.00
- Trailing P/E Ratio 17.84
- Forward P/E Ratio 17.84
- P/E Growth 17.84
- Net Income $55.68 B
Income Statement
Quarterly
Annual
Latest News of RDY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
'Jeopardy!' Contestant Involved in Sexist Clue Incident Speaks Out About the 'Uncomfortable' Moment: 'An Odd Choice'
Liza Esquibias is an Editorial Intern at PEOPLE and a Journalism major at Pepperdine. Jeopardy! contestant Heather Ryan addressed a sexist clue on the show, suggesting better choices for future episod...
By PEOPLE.com | 1 day ago -
'Jeopardy!' boss brushes off sexist clue backlash after host Ken...
"Jeopardy!" producer Sarah Whitcomb Foss addresses the controversial clue involving a sexist rhyming phrase on the game show. Foss and former champion Buzzy Cohen discuss the incident on a podcast, cl...
By New York Post | 1 day ago -
Jordyn Blum Has 'Had Time to Process' Husband Dave Grohl Welcoming Baby Out of Marriage: Source (Exclusive)
Dave Grohl's wife, Jordyn Blum, is coping with the news of his new baby outside their marriage. Sources say she's taking time to process and not making quick decisions, focusing on their daughters. Gr...
By PEOPLE.com | 2 days ago
